medicine-news-1/medical-heroin-helps-treatment-resistant-addicts-54920-3/;msg18067;topicseen

Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6 Sirius Genomics Announces Change in Leadership 2 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4 AEterna Zentaris Announces Appointment of New Board Member 2

[0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain [0] Sirius Genomics Announces Change in Leadership [0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea [0] AEterna Zentaris Announces Appointment of New Board Member

Breaking Medicine Technology:Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 2 Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 3 Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 4 Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 5 Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2 Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6 Elsevier launches online version of the Chinese Journal of Natural Medicines 48452 1 Elsevier launches online version of the Chinese Journal of Natural Medicines 48452 2 Availability of diagnostic tests drive success in hospitalist run short stay units 48448 1 Availability of diagnostic tests drive success in hospitalist run short stay units 48448 2 HCPro Selects Vivisimo Velocity to Launch MedicareFind com 48445 1 HCPro Selects Vivisimo Velocity to Launch MedicareFind com 48445 2 HCPro Selects Vivisimo Velocity to Launch MedicareFind com 48445 3

[0] Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America [0] Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix [0] Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase